Optimal primary surgical treatment for advanced epithelial ovarian cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Elattar, Ahmed ^a   Hatem, Mohamed ^a   Bryant, Andrew ^b   Dickinson, Heather O ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM DERIVATIVE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; COCHRANE LIBRARY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DATA BASE; EMBASE; HUMAN; INFORMATION PROCESSING; MEDLINE; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 70249101309     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007565     Document Type: Review

References (34)

1. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer. Obstetrics and Gynecology 2006; 107:77-85.
2. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers FIGO Committee on Gynecologic Oncology. International Journal of Gynaecology and Obstetrics 2000;70:209-262
3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. Journal of Clinical Oncology 2002;20 (5):1248-1259
4. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Critical Reviews in Oncology/Hematology 2006;60 (2):159-179
5. Covens AL. ACritique of SurgicalCytoreduction in Advanced Ovarian Cancer. Gynecologic Oncology 2000;78:269-274
6. Deeks JJ, Altman DG, BradburnMJ. Statisticalmethods for examining heterogeneity and combining results fromseveral studies inmetaanalysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context. Vol. 2nd edition, London: BMJ Publication Group, 2001.
7. Deffieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. International Journal of Gynecological Cancer 2006; 16 (s1):35-40.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-188
9. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology 1998;69: 103-108
10. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction in ovarian cancer: is there a correlation with "biological aggressiveness" and survival?. Gynecologic Oncology 2001;82: 435-441.
11. Eisenkop SM, Spirtos NM, Friedman RL, Lin WCM, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology 2003;90 (2):390-396
12. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J et al and the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Annals of Oncology 2003;14 (Supplement 5):v61-v118.
13. Fader AN, Rose PG. Role of Surgery in Ovarian Carcinoma. Journal of Clinical Oncology 2007;25 (20):2873-2883
14. Girling JC, Soutter WP. Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: A topic for debate. International Journal of Gynecological Cancer 1996:81-84
15. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. 'Cancer Incidence, Mortality and Prevalence Worldwide'. IARC CancerBase 2004;5:ver 2.0.
16. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Journal of the National Cancer Institute Monographs 1975;42:1014.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. 'Measuring inconsistency in meta-analyses'. BMJ 2003;327:557-560
18. Hoskins WJ, Bundy BN, Thigpen JT. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecologic Oncology 1992;47:159-166
19. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial epithelial ovarian carcinoma: a Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology 1994;170:974-980
20. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis?. American Journal of Obstet- rics and Gynecology 1992;166:504-511
21. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. IARC Scientific Publication No. 155, Lyon 2002;VIII.
22. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics. CA: A Cancer Journal for Clinicians 2008;58:71-96.
23. Markman M. Concept of Optimal Surgical Cytoreduction in Advanced OvarianCancer: A Brief Critique and a Call for Action. Jour- nal of Clinical Oncology 2007;25 (27):4168-4170
24. Munstedt K, Franke FE. Role of primary surgery in advanced ovarian cancer. World Journal of Surgical Oncology 2004;2 (1):32.
25. ParmarMK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-2834
26. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved shortterm survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. International Journal of Gyne- cological Cancer 2006;16 (s1):11-17.
27. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecologic Oncology 2005;97(2):519-523
28. Sharma S, Driscoll DBA, Odunsi K, Venkatadri A, Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. American Journal of Obstetrics and Gynecology 2005;193(6):2077-2082
29. Stoeckle E, Paravis P, Floquet A. Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer. International Journal of Gynecological Cancer 2004;14:779-787
30. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer - Adjuvant Chemotherapy in Ovarian Neoplasm Trial. Journal of the National Cancer Institute 2003;95: 113-125
31. Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstetrics and Gynecology 1992;79:168-172
32. Vergote I, DeWever I, TjalmaW, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients. Gynecologic Oncology 1998;71 (3):431-436
33. Vergote I, Trimbos, Baptist J. Treatment of patients with early epithelial ovarian cancer. Current opinion in Oncology 2003;15 (6):452-455
34. Von Georgi R, Franke FE, Munstedt K. The influence of tumor biology, surgery, and postoperative therapy on patient prognosis in advanced ovarian carcinomas. European Journal of Obstetrics, Gynecol- ogy and Reproductive Biology 2003;111:189-196